Profiles
Professor Matthew Cramp
Chair in Hepatology
Peninsula Medical School (Faculty of Health)
Professor Matthew Cramp can be contacted through arrangement with our Press Office, to speak to the media on these areas of expertise.
- Hepatitis
- Liver
- Obesity
- COVID-19
- Hepatology
- Liver disease
- Alcohol misuse
- Liver transplants
Email publicrelations@plymouth.ac.uk to enquire.
Biography
Biography
Present appointments:
Consultant Hepatologist, Derriford Hospital, University Hospital NHS Trust (1999- present).
Professor of Hepatology, University of Plymouth (2013- present, previously Hon Senior Lecturer in Hepatology 1999-2013)
Head of the Hepatology Research Group, University of Plymouth (2008-present).
Clinical lead for the Peninsula HCV Operational Delivery Network (2015-present)
I hold both NHS and university contracts. As Professor of Hepatology and Head of the Hepatology Research Group I lead a large team delivering an active research programme encompassing laboratory work in our own dedicated labs at the Derriford Research Facility though to a broad portfolio of clinical trials. As a Consultant Hepatologist at the South West Liver Unit I manage patients with all types of liver disease, deliver inpatient and outpatient care, endoscopy and am clinical lead for liver transplantation.
Qualifications
Qualifications:
MB BS St Bartholomews Hospital Medical College June 1987
MRCP Royal College of Physicians (London) July 1990
MD Kings College, University of London Nov 1998
FRCP Royal College of Physicians (London) May 2003
Matthew Cramp is Professor of Hepatology at the Peninsula Medical School and a Consultant Hepatologist at the South West Liver Unit, Derriford Hospital, Plymouth. Since starting single handed he has been able to develop and deliver high quality, comprehensive specialist liver services for patients living in the southwest culminating in the development of the South West Liver Unit.
In parallel with clinical service development, he has built an active clinical trials program with a broad portfolio of over 20 studies currently active. Matthews original research interest was in hepatitis C virus infection and he has been actively involved in helping to drive the rapid progress made in both understanding and treating this prevalent infection – see https://www.plymouth.ac.uk/research/ref2021/health . The research program has grown and diversified and Matthew established the Hepatology Research Group (HRG) at University of Plymouth in 2008. The HRG now delivers a wide ranging program of translational research working in the state of the art laboratory facilities at the Derriford Research Facility, adjacent to Derriford Hospital. The HRG continues to expand, with substantive clinical academic and scientist posts and a growing national and international reputation. The research program is supported by local, regional, and national grants and encompasses viral hepatitis, fatty liver disease, alcohol related liver disease, hepatocellular carcinoma and the potential impact of ingested nanoplastics on liver health.
Professional membership
British Association for the Study of the Liver (BASL)
British Liver Transplant Group (BLTG)
British Viral Hepatitis Group (BVHG)
British Society of Gastroenterology (BSG)
European Association for the Study of the Liver (EASL)
American Association for the Study of Liver Disease (AASLD)
Roles on external bodies
Professor Cramp is actively involved in national service development, research, policy and training in a number of roles including:
- current Chair of the British Liver Transplant Group (2022-2025),
- past President of the British Association for the Study of the Liver (2017-2019)
- founder member of the Lancet Commission on Liver Disease (2014-2021)
- expert clinical advisor to the Hepatobiliary Clinical Reference Group (2015-2022).
He regularly reviews papers for multiple journals and submissions to grant giving bodies including for the MRC, Wellcome and NIHR.
Publications
Publications
Key publications
Key publications are highlighted
Journals
Articles
(2023) 'Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study' The Lancet Gastroenterology & Hepatology 8, (10) 879-907 , DOI
(2023) 'Diagnostic accuracy of serological and imaging tests used in surveillance for hepatocellular carcinoma in adults with cirrhosis: a systematic review protocol' NIHR Open Research 3, 23-23 , DOI Open access
(2023) 'Satellite liver transplant centres significantly improve transplant assessment outcomes for patients with chronic liver disease but not hepatocellular carcinoma: a retrospective cohort study' Frontline Gastroenterology 14, (4) 334-342 , DOI
(2022) 'The Liverpool alcohol‐related liver disease algorithm identifies twice as many emergency admissions compared to standard methods when applied to Hospital Episode Statistics for England' Alimentary Pharmacology & Therapeutics , DOI Open access
(2022) 'Renal dysfunction after liver transplantation for polycystic liver disease' Liver Transplantation 28, (10) 1674-1677 , DOI
(2022) 'Invasive coronary angiography as a tool in cardiac evaluation for liver transplant candidates' Journal of Liver Transplantation 7, , DOI Open access
(2022) 'Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study' The Lancet Gastroenterology & Hepatology 7, (5) 396-415 , DOI
(2022) 'A UK survey on variation in the practice of management of choledocholithiasis and laparoscopic common bile duct exploration (ALiCE Survey)' Surgical Endoscopy 36, (8) 5882-5896 , DOI Open access
(2022) 'Patients with moderate to severe COVID-19 have an impaired cytokine response with an exhausted and senescent immune phenotype' Immunobiology 227, (2) , DOI Open access
(2022) 'Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQβ1' The American Journal of Human Genetics 109, (2) 299-310 , DOI
(2022) 'Intraductal fully covered self-expanding metal stents in the management of post-liver transplant anastomotic strictures: a UK wide experience' Therapeutic Advances in Gastroenterology 15, , DOI Open access
(2021) 'Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581]' Journal of Hepatology 76, (2) 489-489 , DOI
(2021) 'Mapping of population disparities in the cholangiocarcinoma urinary metabolome' Scientific Reports 11, (1) , DOI Open access
(2021) 'Virtual liver transplant assessment: a novel pathway that is likely safe, effective and optimises access to transplantation' Frontline Gastroenterology 13, (4) 360-362 , DOI
(2021) 'Interleukin-2 receptor antibody induction with early low dose tacrolimus preserves post-liver transplant renal function in at risk individuals' Journal of Liver Transplantation 3, , DOI Open access
(2021) 'An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs' Journal of Hepatology 75, (3) 572-581 , DOI Open access
(2021) 'X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis' Gastroenterology 160, (7) 2483-2495.e26 , DOI
(2021) 'Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom–Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa' The Journal of Infectious Diseases , DOI Open access
(2020) 'Correction: Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection' Genes & Immunity 21, (6-8) 420-420 , DOI
(2020) 'Impact of direct‐acting antiviral agents on liver function in patients with chronic hepatitis C virus infection' Journal of Viral Hepatitis 28, (1) 168-176 , DOI Open access
(2020) 'A Multiancestry Sex-Stratified Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus' The Journal of Infectious Diseases 223, (12) 2090-2098 , DOI
(2020) 'Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection' Genes & Immunity 21, (5) 348-359 , DOI
(2020) 'Effect of zinc treatment on clinical outcomes in patients with liver cirrhosis: A systematic review and meta-analysis' World Journal of Hepatology 12, (7) 389-398 , DOI Open access
(2020) 'Effect of zinc treatment on clinical outcomes in patients with liver cirrhosis: A systematic review and meta-analysis' World Journal of Hepatology 12, (7) 390-399 , DOI Open access
(2020) 'Trace element deficiency is highly prevalent and associated with infection and mortality in patients with alcoholic hepatitis' Alimentary Pharmacology & Therapeutics , DOI Open access
(2020) 'Adult liver transplantation: A UK clinical guideline - part 1: pre-operation' Frontline Gastroenterology 11, (5) 375-384 , DOI Open access
(2020) 'Adult liver transplantation: UK clinical guideline - part 2: surgery and post-operation' Frontline Gastroenterology 11, (5) 385-396 , DOI Open access
(2020) 'Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation' American Journal of Transplantation 20, (4) 1125-1136 , DOI Open access
(2020) 'Sequential Cohort Analysis After Liver Transplantation Shows de Novo Extended Release Tacrolimus Is Safe, Efficacious, and Minimizes Renal Dysfunction' Transplantation Direct 6, (2) , DOI Open access
(2019) 'Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK' The Lancet 395, (10219) 226-239 , DOI
(2019) 'Ex Vivo T Cell Cytokine Expression Predicts Survival in Patients with Severe Alcoholic Hepatitis' Gut and Liver , DOI Open access
(2019) 'Intermediate Monocytes in Acute Alcoholic Hepatitis Are Functionally Activated and Induce IL-17 Expression in CD4+ T Cells' The Journal of Immunology 203, (12) 3190-3198 , DOI
(2019) 'Risk-adjusted survival in liver transplant patients assessed and managed by a non-transplanting centre: South West Liver Unit experience' Frontline Gastroenterology 11, (3) 202-208 , DOI
(2019) 'Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6' Journal of Viral Hepatitis 26, (9) 1127-1138 , DOI
(2019) 'Systematic review with meta‐analysis: high mortality in patients with non‐severe alcoholic hepatitis' Alimentary Pharmacology and Therapeutics , DOI Open access
(2019) 'Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom Cohort' Journal of Clinical and Experimental Hepatology 10, (1) 17-29 , DOI
(2019) 'Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis' Journal of Hepatology 71, (4) 660-665 , DOI Open access
(2019) '<p>Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population</p>' Hepatic Medicine: Evidence and Research 11, 47-67 , DOI Open access
(2018) 'Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus' Gastroenterology 156, (5) 1496-1507.e7 , DOI
(2018) 'Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK' The Lancet 392, (10162) 2398-2412 , DOI
(2018) 'Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom' Alimentary Pharmacology and Therapeutics 48, (9) 951-960 , DOI Open access
(2018) 'Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score' The Lancet Gastroenterology & Hepatology 3, (9) 626-634 , DOI
(2018) 'Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial' Hepatology 67, (6) 2113-2126 , DOI
(2017) 'Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK' The Lancet 391, (10125) 1097-1107 , DOI
(2017) 'Enhanced natural killer cell activity is found in exposed uninfected recipients of hepatitis C-contaminated blood' Journal of Viral Hepatitis 25, (3) 245-253 , DOI Open access
(2017) 'Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection' Scientific Reports 7, , DOI Open access
(2017) 'Lipid interactions influence hepatitis C virus susceptibility and resistance to infection' Clinical Liver Disease 10, (1) 17-20 , DOI Open access
(2017) 'Exploration of potential mechanisms of HCV resistance in exposed uninfected intravenous drug users' Journal of Viral Hepatitis , DOI Open access
(2017) 'Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study' The Lancet Gastroenterology & Hepatology 2, (5) 325-336 , DOI
(2017) 'Infection does not increase long-term mortality in patients with acute severe alcoholic hepatitis treated with corticosteroids' World Journal of Gastroenterology 23, (11) 2052-2052 , DOI Open access
(2017) 'Hepatorenal syndrome: Update on diagnosis and therapy' World Journal of Hepatology 9, (6) 293-293 , DOI Open access
(2016) 'New metrics for the Lancet Standing Commission on Liver Disease in the UK' The Lancet 389, (10083) 2053-2080 , DOI
(2016) 'Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study' The Lancet Gastroenterology & Hepatology 2, (3) 161-176 , DOI
(2016) 'Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection' Journal of Viral Hepatitis 23, (11) 873-880 , DOI Open access
(2016) 'Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy' Journal of Clinical and Experimental Hepatology 6, (3) 186-194 , DOI
(2015) 'Diagnosis and management of hepatitis C' British Journal of Hospital Medicine 76, (11) 625-630 , DOI
(2015) 'Implementation of the Lancet Standing Commission on Liver Disease in the UK' The Lancet 386, (10008) 2098-2111 , DOI
(2015) 'The UK‐PBC risk scores: Derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cholangitis' Hepatology 63, (3) 930-950 , DOI
(2015) 'International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways' Nature Communications 6, (1) , DOI Open access
(2015) 'Haplotype analysis finds linkage disequilibrium in the IL-12 gene in patients with HCV' J Med Virol 87, (7) 1207-1217 , DOI
(2015) 'HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact' JOURNAL OF VIRAL HEPATITIS 22, (4) 399-408 , DOI Open access
(2014) 'Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis' Lancet 384, (9958) 1953-1997 , DOI
(2014) 'Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis' Lancet 384, (9958) 1953-1997
(2014) 'Impaired functional capacity in potential liver transplant candidates predicts short-term mortality before transplantation' Liver Transpl 20, (9) 1081-1088 , DOI
(2014) 'Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study' J Clin Exp Hepatol 4, (3) 221-225 , DOI
(2014) 'Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality' BMC Gastroenterol 14, , DOI Open access
(2014) 'Polymorphic differences in SOD-2 may influence HCV viral clearance' J Med Virol 86, (6) 941-947 , DOI
(2014) 'Historical epidemiology of hepatitis C virus (HCV) in selected countries' J Viral Hepat 21 Suppl 1, 5-33 , DOI
(2014) 'Strategies to manage hepatitis C virus (HCV) disease burden' J Viral Hepat 21 Suppl 1, 60-89 , DOI
(2014) 'The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm' J Viral Hepat 21 Suppl 1, 34-59 , DOI
(2013) 'Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection' Hepatology 58, (3) 881-889 , DOI
(2013) 'Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts' Ann Intern Med 158, (4) 235-245 , DOI
(2012) 'Cytokine profiles in high risk injection drug users suggests innate as opposed to adaptive immunity in apparent resistance to hepatitis C virus infection' J Viral Hepat 19, (7) 501-508 , DOI
(2012) 'Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis' Eur J Gastroenterol Hepatol 24, (5) 543-550 , DOI
(2012) 'Cholestasis secondary to progesterone' Archives of Disease in Childhood - Fetal and Neonatal Edition 97, (Suppl 1) A69.3-A69 , DOI
(2012) 'POTENTIAL IMPACT OF PROTEASE INHIBITORS IN THE SOUTH WEST PENINSULA HEPATITIS C POPULATION' GUT 61, A140-A141 , DOI
(2011) 'OP04 Synergistic influence of tapasin and HLA class I protection against chronic Hepatitis C virus infection' Gut 60, (Suppl 2) A51-A52 , DOI
(2011) 'P45 Natural killer cell cytotoxicity is enhanced in injection drug users with apparent resistance to hepatitis C virus infection' Gut 60, (Suppl 2) A21-A22 , DOI
(2011) 'P80 Patient characteristics and outcomes in a 'Hub and Spoke Model' for liver transplantation provision: The South West Liver Unit/King's College Experience' Gut 60, (Suppl 2) A37-A37 , DOI
(2011) 'Treatment of autoimmune hepatitis: a review of current and evolving therapies' J Gastroenterol Hepatol 26, (4) 619-627 , DOI
(2011) 'Loss of virus-specific T-cell responses in HCV exposed uninfected injection drug users with drug rehabilitation' J Infect Dis 203, (6) 847-853 , DOI
(2011) 'A Polymorphism in <i>IL28B</i> Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection' GASTROENTEROLOGY 141, (1) 320-U419 , DOI
(2010) 'P14 Mycophenolate mofetil in patients with autoimmune hepatitis intolerant to azathioprine' Gut 59, (Suppl 2) , DOI
(2010) 'P68 PACIFIC: a phase III, randomised, multicentre, dose escalation, efficacy and safety study examining the effects of treatment with peginterferon alfa-2a in patients with Child's A or B cirrhosis in chronic hepatitis C virus infection' Gut 59, (Suppl 2) , DOI
(2010) 'Consistent Beneficial Effects of Killer Cell Immunoglobulin-Like Receptor 2DL3 and Group 1 Human Leukocyte Antigen-C Following Exposure to Hepatitis C Virus' HEPATOLOGY 51, (4) 1168-1175 , DOI
(2009) 'ANTIVIRAL ACTIVITY AND SAFETY OF TMC435 COMBINED WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION WHO FAILED PREVIOUS IFN-BASED THERAPY' JOURNAL OF HEPATOLOGY 50, S385-S385 , DOI
(2008) 'Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection' Clin Exp Immunol 152, (3) 538-541 , DOI
(2008) 'Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis' Br J Cancer 98, (7) 1166-1175 , DOI Open access
(2007) 'Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis' Health Technol Assess 11, (34) 1-206 , DOI
(2006) 'Case finding for hepatitis C in primary care: a cost utility analysis' Fam Pract 23, (4) 393-406 , DOI
(2006) 'Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression' Int J STD AIDS 17, (1) 67-69 , DOI
(2006) 'The cost-effectiveness of testing for hepatitis C in former injecting drug users' Health Technology Assessment 10, (32) 1-+
(2005) 'Polymorphisms in the IL-12B gene and outcome of HCV infection' J Interferon Cytokine Res 25, (5) 271-276 , DOI
(2005) 'Non-travel-associated Hepatitis C in England and Wales: Demographic, clinical, and molecular epidemiological characteristics' Journal of Infectious Diseases 192, (7) 1166-1172
(2004) 'HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection' Science 305, (5685) 872-874 , DOI
(2004) 'Direct evidence that naturally occurring mutations within hepatitis B core epitope alter CD4+ T-cell reactivity' J Med Virol 72, (3) 370-376 , DOI
(2004) 'Screening for hepatitis C virus in the Dartmoor prison population: an observational study' Journal of Public Health 26, (4) 372-375
(2003) 'Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT' AMERICAN JOURNAL OF GASTROENTEROLOGY 98, (7) 1588-1593 , DOI
(2003) 'Traditional Chinese medicine in the treatment of chronic HCV infection' Gut 52, (5)
(2002) 'Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy' Liver 22, (5) 404-412 , DOI
(2002) 'Re: Whither smooth muscle antibodies in the third millennium?' J Clin Pathol 55, (7) 558-559 , DOI
(2002) 'Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases' J Hepatol 36, (2) 295-301 , DOI
(2002) 'Acute hepatitis A virus infection: a review of prognostic factors from 25 years experience in a tertiary referral center' Hepatogastroenterology 49, (44) 524-528
(2001) 'Liver transplantation in adults coinfected with HIV' Transplantation 72, (10) 1684-1688 , DOI
(2001) 'Liver Transplantation in Adults Coinfected With HIV. Transplantation 2001; 72: 1684' Transplantation 72, (10) 1594-1595 , DOI
(2000) 'Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg)' J Am Acad Dermatol 43, (2 Pt 2) 403-408 , DOI
(2000) 'Scleromyxedema: Response to high-dose intravenous immunoglobulin (hdIVIg)' Journal of the American Academy of Dermatology 43, (2) 403-408 , DOI
(2000) 'Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C' Gastroenterology 118, (2) 346-355 , DOI
(2000) 'Liver histology and progression of fibrosis in individuals with chronic hepatitis C virus infection and persistently normal ALT' HEPATOLOGY 32, (4) 285A-285A
(1999) 'The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre' Gut 44, (4) 563-567 , DOI
(1999) 'Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia' Gut 44, (3) 424-429 , DOI
(1998) 'Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia' J Hepatol 29, (2) 207-213 , DOI
(1998) 'The influence of the HLA class II allele DQB1∗0301 on HCV specific T helper cell responses' Journal of Hepatology 28, 94-94 , DOI
(1997) 'Book Review: Diseases of the Liver and Biliary System' Journal of the Royal Society of Medicine 90, (10) 584-584 , DOI
(1997) 'Hepatitis in alcohol and drug misusers: practical issues' Addiction Biology 2, (4) 411-420 , DOI
(1996) 'Seroprevalence of hepatitis B and C virus in two institutions caring for mentally handicapped adults' J R Soc Med 89, (7) 401-402
(1996) 'Bile acid malabsorption in HIV infected patients with chronic diarrhoea' Aust N Z J Med 26, (3) 368-371 , DOI
(1994) 'Cutaneous manifestations of mycobacterial infection in patients with AIDS' Br J Dermatol 130, (1) 111-114 , DOI
(1992) 'Case report: pneumatosis intestinalis occurring in association with cryptosporidiosis and HIV infection' Clin Radiol 46, (6) 410-411 , DOI
(1992) 'Rapid high-flux dialysis can cure uraemic peripheral neuropathy' Nephrol Dial Transplant 7, (6) 539-540
Letters
(2010) 'Limitations of the Algorithm for the SAFE Biopsy: A Noninvasive Fibrosis Measure in Chronic Hepatitis C' HEPATOLOGY 51, (1) 354-355 , DOI
(2009) 'Elastography for the non-invasive assessment of liver disease: limitations and future developments' GUT 58, (8) 1171-1172
Chapters
(2020) 'Hepatitis viruses (excluding hepatitis C virus)' Oxford Textbook of Medicine Oxford University PressOxford 889-C8.5.21.P45 , DOI
Conference Papers
(2016) 'C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naive and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks' 39A-40A
(2016) 'Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin' 455A-456A
(2016) 'Sustained viral clearance of HCV with DAA treatment is associated with restoration of effector T cell phenotype' 745A-745A
(2016) 'Predicting Fatty Liver Disease in Healthy Potential Liver Donors' Elsevier BV S479-S479 , DOI
(2016) 'SOFOSBUVIR/VELPATASVIR FIXED DOSE COMBINATION FOR 12 WEEKS IN HCV INFECTED PATIENTS PREVIOUSLY TREATED WITH PLACEBO: RESULTS OF THE DEFERRED TREATMENT STUDY (GS-US-342-1446 STUDY)' S827-S828
(2015) 'PTH-100 A comparative gene expression study between individuals with apparent resistance, spontaneous clearance, or chronic infection from hcv' BMJ A452.1-A452 , DOI
(2015) 'PTH-124 Liver transplant outcomes in patients with care devolved to a non-transplanting centre: south west liver unit experience' BMJ A462.2-A463 , DOI
(2015) 'LP11 : Warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C): results at one year' Elsevier BV S268-S269 , DOI
(2014) 'P210 ALTERATIONS IN CXCR3/CXCL10 BUT NOT CCR5 IN HCV ARE ASSOCIATED WITH VIRAL INHIBITION WITH INTERFERON-FREE DIRECT ACTING ANTIVIRAL THERAPY' Elsevier BV S136-S136 , DOI
(2014) 'P790 REDUCING THE DISEASE BURDEN OF CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN ENGLAND' Elsevier BV S333-S334 , DOI
(2014) 'Neutralising anti-envelope antibodies in uninfected individuals that are repeatedly exposed to HCV' 1057A-1057A
(2013) 'ARE CURRENT TREATMENT RATES SUFFICIENT TO REDUCE HCV PREVALENCE AMONG PEOPLE WHO INJECT DRUGS? MODEL PROJECTIONS IN SEVEN UK SETTINGS' S356-S356 , DOI
(2013) 'THE USE OF CARDIOPULMONARY EXERCISE TESTING IN PREDICTING PRE- AND POST-OPERATIVE MORTALITY IN LIVER TRANSPLANT CANDIDATES' S412-S412 , DOI
(2011) 'Synergistic influence of tapasin and HLA class I protection against chronic hepatitis C virus infection' 173-173
(2011) 'NATURAL KILLER CELL CYTOTOXICITY IS ENHANCED IN INJECTION DRUG USERS WITH APPARENT RESISTANCE TO HEPATITIS C VIRUS INFECTION' 1322A-1322A
(2011) 'ABSENCE OF <i>IL</i>-<i>28</i>B PROTECTION IN INDIVIDUALS EXPOSED TO HEPATITIS C VIRUS DEMONSTRATES DISCRETE GENETIC PATHWAYS FOR PROTECTION AGAINST CHRONIC HCV INFECTION' S38-S39 , DOI
(2010) 'INDIVIDUALIZED CONCENTRATION MONITORED HIGH DOSE RIBAVIRIN IN COMBINATION WITH PEGINTERFERON TO HEPATITIS C GENOTYPE 1 PATIENTS WITH PREVIOUS NONRESPONSE' 710A-711A
(2010) 'PACIFIC: A PHASE III, RANDOMIZED, MULTICENTER, DOSE ESCALATION, EFFICACY AND SAFETY STUDY EXAMINING THE EFFECTS OF TREATMENT WITH PEGINTERFERON ALFA-2A IN PATIENTS WITH CHILD'S A OR B CIRRHOSIS IN CHRONIC HEPATITIS C VIRUS INFECTION' 710A-710A
(2010) 'PREDICTORS OF HEPATITIS C TREATMENT OUTCOME IN GENOTYPE 1 PATIENTS IN A "REAL WORLD" SETTING' A77-A77 , DOI
(2009) 'ASSOCIATION OF HLA AND NK CELL INHIBITORY RECEPTOR WITH APPARENT RESISTANCE TO HEPATITIS C INFECTION' 386A-386A
(2009) 'CELLULAR DISTRIBUTION OF CLAUDIN 1 IN LIVER TISSUE IN HEPATITIS C AND OTHER LIVER DISEASES' 950A-950A
(2009) 'CYTOKINE PROFILES IN HCV EXPOSED BUT UNINFECTED CASES WITH APPARENT RESISTANCE TO HCV INFECTION' 936A-936A
(2009) 'LONGITUDINAL ANALYSIS OF HEPATITIS C VIRUS SPECIFIC T CELL RESPONSES IN EXPOSED UNINFECTED INTRAVENOUS DRUG USERS' A17-A17
(2009) 'LONGITUDINAL ANALYSIS OF HCV SPECIFIC T-CELL RESPONSES IN EXPOSED UNINFECTED INTRAVENOUS DRUG USERS' S326-S326 , DOI
(2008) 'Hepatitis C virus (HCV)--specific T cell responses in injection drug users with apparent resistance to HCV infection' United States 1749-1755 , DOI
(2008) 'Audit of management of alcohol withdrawal at derriford hospital' A72-A72
(2008) 'Mycophenolate mofetil in patients with refractory autoimmune hepatitis' A71-A72
(2007) 'HCV-specific cellular immune responses in intravenous drug users without HCV infection' 240A-241A
(2007) 'Interleukin 12B gene polymorphism and apparent resistance to HCV infection' 890A-891A
(2007) 'Single nucleotide polymorphism of the SRB1 gene and susceptibility to HCV infection' A134-A135
(2006) 'Late spontaneous clearance of hepatitis C' A43-A43
(2004) 'Endoscopic sphincterotomy is sufficient treatment for most post cholecystectomy bile leaks' A44-A44
(2003) 'IL-12 gene polymorphism and outcome of HCV infection' 356A-356A
(2003) 'Specific antibody titres vary over time in individuals with chronic HCV infection and persistently negative HCV RNA'
(2002) 'Specific antibody titres vary over time in individuals with chronic HCV infection and persistently negative HCV RNA' 552A-552A
(2002) 'Traditional Chinese medicine in the treatment of chronic HCV infection' 569A-569A
(2000) 'Reactivation of latent hepatitis B virus infection with HIV related immunosuppression' 454A-454A
(1999) 'The association of the Arg25Pro polymorphism in the TGFβ1 gene with fibrosis in chronic hepatitis C patients' 331A-331A
(1999) 'HCV-specific immune responses in HCV exposed but uninfected cases' A97-A97
(1998) 'HCV-specific T helper cell responses in HCV exposed but uninfected cases' 200A-200A
(1998) 'HLA class III and class II alleles in hepatitis C virus infection and outcome' 159-160
(1998) 'Interferon induced virus specific T helper cell responses are associated with viral clearance in chronic HCV infection' 155-155
(1998) 'Mutations within a promiscuous immunodominant epitope in hepatitis B core protein and their effect on T helper cell response' 156-157
(1998) 'The influence of the HLA class II allele DQB1*0301 on HCV specific T helper cell responses' A21-A21
(1997) 'Interferon induced virus specific T helper cell responses are associated with viral clearance in chronic HCV infection' 1111-1111
(1997) 'Reduced production of interleukin-12 by PBMC from patients with chronic hepatitis C' 1121-1121
(1997) 'T helper cell response to mutations within a promiscuous immunodominant epitope in acute and chronic hepatitis B' 1953-1953
(1997) 'Tumor necrosis factor gene polymorphisms in hepatitis C virus infection' 1413-1413
(1997) 'Beneficial in vitro effects of tucaresol on the immune response to hepatitis C virus' TH119-TH119
(1996) 'A multispecific T lymphocyte response to hepatitis C virus proteins occurs in patients with viral clearance and persists many years after exposure' 503-503
(1996) 'Evidence that HLA class II genotype may be associated with clearance of hepatitis C virus' 99-99
Reports
Presentations and posters
'High-Level Resistance to Hepatitis C - A Possible Role for Innate Immunity'
'HCV-specific cellular immune responses in subjects exposed to but uninfected by HCV' Open access
'Selonsertib in Combination with Prednisolone for the Treatment of Severe Alcoholic Hepatitis: A Phase 2 Randomized Controlled Trial' , DOI
'HCV-specific cellular immune responses in subjects exposed, but uninfected by HCV' , DOI Open access
'A NOVEL FUNCTIONAL BIOASSAY PREDICTS 90-DAY SURVIVAL IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS' , DOI Open access
'A UK Survey on Variation in Practice of Management of Choledocholithiasis and Laparoscopic Common Bile Duct Exploration (ALiCE Survey)' , DOI
'Autoantibodies to apolipoprotein A-1 in chronic hepatitis C infection: a role in hepatic fibrosis and cirrhosis?' , DOI
'Corticosteroid treatment is associated with a resolution of altered CD4+ T cell phenotype in patients with severe alcoholic hepatitis' , DOI
'Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study' , DOI
'Elbasvir/grazoprevir plus sofosbuvir in treatment-naive and treatment-experienced cirrhotic patients with hepatitis C virus genotype 3 infection treated for 8, 12, or 16 weeks: final results of the C-ISLE study' , DOI
'Formal referral networks optimise patient selection for liver transplantation' , DOI
'HPB O07 Complication profile of laparoscopic common bile duct exploration: Results from R-ALiCE Study' , DOI
'Inequality in access to liver transplant: are satellite liver transplant centres the answer?' , DOI
'Intermediate (CD14++CD16+) monocytes from patients with acute severe alcoholic hepatitis are activated and functionally similar to classical (CD14++CD16−) monocytes' , DOI
'Long term albumin administration is associated with reduced healthcare resource use in patients with uncomplicated cirrhotic ascites: results from a simulation model' , DOI
'OTU-11 Non-severe alcoholic hepatitis is not a benign condition: systematic review and meta-analysis of mortality data' , DOI
'P026 Differential epigenetic regulation in survivors and non-survivors from severe alcoholic hepatitis' , DOI
'P03 Mortality from severe alcoholic hepatitis is associated with increased oxidative stress and epigenetic alterations' , DOI
'P044 Healthcare recourse use in patients with cirrhotic ascites: a UK real world evidence study' , DOI
'P085 Virtual transplant assessment is feasible and may increase access to liver transplantation' , DOI
'P215 Universal tumour antigens in primary liver neoplasms: cholangiocarcinoma and hepatocellular carcinoma differ' , DOI
'P98 Formal regional referral networks optimize patient selection for liver transplantation' , DOI
'SAT-122-Cirrhotic cardiomyopathy: An observational study pre-liver transplant' , DOI
'SAT-221-Autoantibodies to apolipoprotein A1 (apoA-1): A new prognostic biomarker in HCV infection' , DOI
'Seeking genetic determinants of resistance to hepatitis C virus infection in a highly resistant cohort' , DOI
'Successful treatment of patients with HCV GT3 infection and cirrhosis with elbasvir/grazoprevir plus sofosbuvir does not correct insulin resistance by 12 weeks post-treatment' , DOI
'Towards elucidating a universal panel of diagnostic biomarkers for early hepatocellular carcinoma' , DOI
'Upregulated innate immune responses in a hepatitis C virus exposed uninfected cohort' , DOI
'Can We Get Consensus on the Best Surgical Approach to Symptomatic Gallstones and Common Bile Duct Stones? Results from a Prospective Multi-centre UK Wide Study (P-ALICE)' , DOI
'Laparoscopic Common Bile Duct Exploration: Results From a Prospective Multi-centre Prospective UK-wide Study (P-ALiCE)' , DOI
'Outcomes of Laparoscopic Common Bile Duct Exploration: Results from a Multi-centre UK-wide Study (R-ALiCE)' , DOI
'Trans-cystic versus Trans-choledochal Approach for Treating Common Bile Duct Stones: Which Approach Is Better? Results from R-ALICE Study' , DOI
'Variations in the Trans-choledochal Laparoscopic Bile Duct Exploration: Is this Time for Consensus Guidelines? Results from a Retrospective Multi-centre Study (R-ALICE)' , DOI
'CD81 sequence and susceptibility to HCV infection'